Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Hansa Biopharma AB (HNSA – Research Report). The associated price target remains the same with SEK143.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Douglas Tsao has given his Buy rating due to a combination of factors surrounding Hansa Biopharma AB’s promising developments in treating Guillain-Barre Syndrome (GBS) with imlifidase. The company recently highlighted the potential of imlifidase to become a standard of care for GBS, an area with significant unmet medical needs, during a virtual investor call featuring key opinion leaders. These experts emphasized the rapid action of imlifidase in reducing IgG levels, which aligns with the ideal treatment profile for the acute phase of GBS, thus offering a promising alternative to current therapies like plasma exchange and IVIg that have not been FDA-approved.
Furthermore, the Phase 2 study results demonstrated that imlifidase, when combined with IVIg, showed superior treatment outcomes compared to IVIg alone, as evidenced by a shorter median time to improvement. This was supported by an indirect analysis using the IGOS real-world dataset, which further validated the efficacy of imlifidase. These findings, along with the anticipation of Phase 3 readouts in kidney transplantation and anti-GBM disease, underpin Tsao’s confidence in the stock’s potential, leading to the Buy rating.